United Therapeutics Corporation · NASDAQ:UTHR
Rothblatt Martine A sold 9,500 United Therapeutics Corporation shares (Form 4)
Traded Sep 2, 2026 · Filed Sep 3, 2026
On Sep 2, 2026, Rothblatt Martine A (Director, Chairperson & CEO) sold 9,500 United Therapeutics Corporation shares at an average US$493.46 for US$4.69M under a trading plan, leaving 324,443 shares. Filed Sep 3, 2026 (Form 4).
- Sold
- 9,500 shares
- Price
- US$493.46 average (US$477.70 to US$510.05)
- Value
- US$4.69M
- Holding after
- 324,443 shares (held indirectly)
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director, Chairperson & CEO
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Common Stock | Option exercise | 9,500 | US$135.42 | 333,943 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 120 | US$477.70 | 333,823 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 160 | US$478.85 | 333,663 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 160 | US$479.89 | 333,503 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 80 | US$482.61 | 333,423 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 120 | US$485.12 | 333,303 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 160 | US$486.32 | 333,143 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 240 | US$489.06 | 332,903 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 560 | US$490.19 | 332,343 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 1,833 | US$491.38 | 330,510 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 2,067 | US$492.25 | 328,443 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 520 | US$493.59 | 327,923 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 520 | US$494.33 | 327,403 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 423 | US$495.95 | 326,980 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 777 | US$496.95 | 326,203 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 364 | US$498.21 | 325,839 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 542 | US$498.97 | 325,297 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 54 | US$500.22 | 325,243 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 160 | US$501.06 | 325,083 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 120 | US$502.01 | 324,963 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 200 | US$504.15 | 324,763 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 40 | US$505.20 | 324,723 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 40 | US$506.27 | 324,683 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 80 | US$508.36 | 324,603 | Indirect |
| Sep 2, 2026 | Common Stock | Sale | 160 | US$510.05 | 324,443 | Indirect |
Source
Related
- United Therapeutics Corporation
- Rothblatt Martine A
- United Therapeutics Corporation shareholders
- Form 4 · Rothblatt Martine A · Oct 22, 2026
- Form 4 · Rothblatt Martine A · Oct 21, 2026
- Form 4 · Rothblatt Martine A · Oct 20, 2026
- Form 4 · Rothblatt Martine A · Oct 19, 2026
- Form 4 · Rothblatt Martine A · Oct 16, 2026
- Schedule 13G/A · Rothblatt Martine A · Aug 14, 2026
- Schedule 13G/A · Wellington Management Group LLP · Aug 13, 2026
- Schedule 13G · Vanguard Capital Management LLC · Apr 30, 2026
- Schedule 13G/A · The Vanguard Group · Mar 27, 2026
- Schedule 13G · Wellington Management Group LLP · Feb 10, 2026